Clinical Trials
Thursday, October 10th, 2013
CIRCULATIONAHA: September 30, 2013 Background—The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. Methods and Results—Two independent investigators reviewed bleeding reports from 1,034 individuals with 1,121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27,419 patients treated for […]
Clinical Trials
Friday, October 4th, 2013
CIRCINTERVENTIONS: October 1, 2013 Background—Carotid artery stenting (CAS) has become an alternative treatment for patients presenting symptomatic carotid artery stenosis. The improvement in clinical outcomes with CAS has been associated with the development of embolic protection devices. The trial aim is to compare flow reversal versus filter protection during CAS through femoral access. Methods and Results—Patients […]
Clinical Trials
Friday, October 4th, 2013
JACC: 10/1.13 Objective Evaluate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors and the CHA2DS2VASc risk score in patients with atrial fibrillation (AF). Background Troponin is a powerful predictor of cardiovascular events and mortality. Methods 14,897 patients with AF randomized to apixaban or warfarin in the ARISTOTLE trial. The associations between baseline hs-TnT […]
Clinical Trials
Friday, October 4th, 2013
BMC Medical Research Methodology: September 28, 2013 Background Interventions targeting individuals classified as “high-risk” have become common-place in health care. High-risk may represent outlier values on utilization, cost, or clinical measures. Typically, such individuals are invited to participate in an intervention intended to reduce their level of risk, and after a period of time, a follow-up […]
Clinical Trials
Friday, October 4th, 2013
The Lancet Neurology: September 27, 2013 Background In animal models of ischaemic stroke, 25% albumin reduced brain infarction and improved neurobehavioural outcome. In a pilot clinical trial, albumin doses as high as 2 g/kg were safely tolerated. We aimed to assess whether albumin given within 5 h of the onset of acute ischaemic stroke increased […]
Clinical Trials
Friday, October 4th, 2013
Health Affairs: 9/10/13 Although we have witnessed historic lows in the rate of growth of healthcare spending, the implementation of the Affordable Care Act and secular trends have created fundamentally new dynamics in how providers, clinicians, and patients are exposed to the cost of care. New payment and delivery models being tested by the Center for […]
Clinical Trials
Friday, September 27th, 2013
AHA Stroke: August 6, 2013 Background and Purpose—We investigated the sensitivity and reliability of MRI susceptibility-weighted imaging (SWI) compared with routine MRI T2*-weighted gradient-recalled echo (GRE) for cerebral microbleed (CMB) detection. Methods—We used data from a prospective study of cerebral amyloid angiopathy (n=9; mean age, 71±8.3) and healthy non–cerebral amyloid angiopathy controls (n=22; mean age, 68±6.3). […]
Clinical Trials
Friday, September 27th, 2013
AHA Stroke: July 25, 2013 Background and Purpose—To assess the effects of intensive and moderate public education on knowledge of early stroke symptoms among a general Japanese population. Methods—Information on early stroke symptoms was distributed by leaflet 12× and by booklet twice in an intensive intervention area >22 months, and by leaflet and booklet once each in […]
Clinical Trials
Friday, September 27th, 2013
AHA Stroke: July 23, 2013 Background and Purpose—In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol. Preliminary analysis […]
Clinical Trials
Monday, September 23rd, 2013
STROKEAHA: September 19, 2013 A Retrospective Analysis of Clinical Trial Data Background and Purpose—Quality of life (QoL) is important to stroke survivors yet is often recorded as a secondary measure in acute stroke randomized controlled trials. We examined whether commonly used stroke outcome measures captured aspects of QoL. Methods—We examined primary outcomes by National Institutes […]
